A new international study reveals that GLP-1 receptor agonists—commonly used for weight loss—may significantly reduce the risk of dementia in people with type 2 diabetes, outperforming metformin.

USA: A recent study published in JAMA Network Open has found that the use of glucagon-like peptide-1 (GLP-1) receptor ...

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six ...

People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

A study from Florida State University uncovers biological and behavioral consequences of weight loss underlying binge-eating in women with bulimia nervosa and related syndromes. The work is published ...

Appetite suppression will always be at its highest on days one to three after injecting Mounjaro and by days six to seven, ...

Source: Analyst estimates for the quarter provided by FactSet.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.